We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Timothy Price

Timothy J Price MBBS, DHlthSc, FRACP

Associate Professor, University of Adelaide School of Medicine, Adelaide, South Australia; Head of Unit, Haematology and Oncology; Head of Clinical Cancer Research, The Queen Elizabeth Hospital–Central Adelaide Social Health Network, Woodville, South Australia

A/Prof Price’s research interest has been gastrointestinal cancer since 1998 when he was accepted for a Gastrointestinal Clinical Research Fellowship at the Royal Marsden Hospital in London. Since returning to Adelaide in 2000 he has had a pivotal role in the ongoing development of the Clinical Research Unit at The Queen Elizabeth Hospital and he currently holds the position of “Head of Clinical Oncology Research”. In May of 2004 he was appointed a Director of the Australasian Gastrointestinal Trials Group board and became a member of the group’s scientific advisory committee, is the Chair of the Upper GI Working party and is now the Chair-elect of the group. A/Prof Price’s research has focused on chemotherapy and molecular targeted therapies for gastrointestinal cancer. A/Prof Price has authored or co-authored over 100 publications in peer reviewed journals. He has presented data regularly as first author and in collaboration at the American Society of Clinical Oncology, European Society of Medical Oncology and the ASCO Gastrointestinal Symposium.

Disclosures

1. Serve(d) on Advisory Boards for: AMGEN and MERCK

Recent Contributions to PracticeUpdate:

  1. Panitumumab vs Cetuximab in Metastatic CRC